Marek Hraska Selected Research

S-1,2-dichlorovinyl-N-acetylcysteine

1/2022	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.
1/2022	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
1/2021	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.
1/2021	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marek Hraska Research Topics

Disease

2	Ovarian Epithelial Carcinoma 01/2022 - 01/2022
2	Neoplasms (Cancer) 01/2022 - 01/2022
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021

Drug/Important Bio-Agent (IBA)

4	S-1,2-dichlorovinyl-N-acetylcysteineIBA 01/2022 - 01/2021
3	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2021
1	VaccinesIBA 01/2022
1	Poly I-CIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	PlatinumIBA 01/2021
1	Gemcitabine FDA Link 01/2021

Therapy/Procedure

3	Immunotherapy 01/2022 - 01/2021
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2021